doi: 10.1038/s41392-024-01931-z
10 This is especially important as GLP-1 receptor agonists confer multiple benefits for patients with diabetes, including better glucose control and weight loss
It also has another obesity drug moving to late-stage clinical trials, eloralintide, with promising data that further builds on [Lillys] leadership position in the obesity and Type 2 diabetes market, according to a Nov
Semaglutide has not been removed from the FDA shortage list the same way tirzepatide has, so compounded access continues in many markets
When combined with changes in diet and exercise, this class of drugs outperforms other diabetes and obesity medications
The preclinical data showing enhanced tendon healing, ligament repair, and injury recovery is genuinely compelling, and ongoing research may eventually establish clear clinical protocols